

Where Nature Meets Bioinformatics: A New Era of Drug Discovery

Maria Zafar^{*1}, Saman Ayub², Hamna Ahsan², Faiqa Asghar³ and Aleena Ramzan⁴

1. Department of Biochemistry, University of Agriculture Faisalabad, Pakistan
2. Department of Bioinformatics, Quaid-e-Azam University, Islamabad, Pakistan
3. Department of Zoology, University of Gujrat, Gujrat, Pakistan
4. Department of Biological and Chemical Sciences, University of Rasul, Mandi Bahauddin

*Corresponding Author: mariazafar.biochemist@gmail.com

ABSTRACT

Computational bioinformatics and natural product chemistry are converging in ways that are reshaping how new drugs get discovered. Molecular docking, virtual screening, and ADMET prediction now let researchers explore the chemistry of plants, fungi, marine organisms, and microbes with the precision no wet lab could match on its own. With antimicrobial resistance (AMR) killing millions each year, these in silico methods offer something the field badly needs: a faster, cheaper route from natural compound to drug candidate. This article walks through that integrated computational-experimental pipeline, points to real applications already underway in oncology, metabolic disease, and antimicrobial research, and argues that the approach holds particular promise for researchers working in biodiversity-rich but resource-limited regions.

Keywords: Computational Bioinformatics, Molecular docking, Antimicrobial resistance, virtual screening, and natural product chemistry

To cite this article: Zafar M, S Ayub, H Ahsan, F Asghar & A Ramzan. Where Nature Meets Bioinformatics: A New Era of Drug Discovery. Biological Times. 2026. September 5(9): 16-18.

Introduction

Nature has been running the world's longest drug discovery program, long before anyone gave it that name. And most of it remains untested. Fewer than one-tenth of the planet's biodiversity has ever been formally screened for biological activity [1]. Somewhere in that unscreened majority sits the next generation of medicines, waiting to be found.

For most of the twentieth century, that search happened slowly, through serendipity, folklore, and years of painstaking bench chemistry. Alexander Fleming noticed in 1928 that a stray mold was killing off bacteria in his petri dish, and the world got penicillin. Paclitaxel took a similarly winding route, from the bark of the Pacific yew to the pharmacy shelf. Then, by the 1990s, pharmaceutical companies mostly walked away from natural products. Combinatorial chemistry was easier to screen at scale, and complex natural compounds were, frankly, a hassle [2]. That retreat is reversing now. As synthetic pipelines run out of answers against resistant pathogens, interest in natural products as drug leads is picking back up [2]. It's hard to overstate how urgent this is. Bacterial AMR was linked to more than 4.71 million deaths globally in 2021 alone [3], and without effective action, that toll could climb to 39 million cumulative deaths by 2050 [3]. Meanwhile, the conventional drug pipeline, ten to fifteen years and upwards of US\$2 billion per approved drug [4], simply wasn't built to move at the speed this crisis demands.

What follows traces how computational tools are helping close that gap, from building natural-product chemical libraries, through virtual screening, molecular docking, ADMET prediction, and molecular dynamics simulation, all the way to experimental validation. And it looks ahead to where AI and genome mining are pushing the frontier next.

Nature's Pharmacy: Ancient Wisdom, Modern Urgency

None of this is accidental. Millions of years of evolution and ecological competition pushed living organisms to develop compounds with remarkable chemical diversity and biological specificity. Plants, fungi, microorganisms, and marine life all evolved under different pressures, in different niches, and their metabolites carry that history, often hitting molecular targets that synthetic chemistry has never quite managed to reach. The record backs this up. Natural products and their derivatives make up over a third of all approved small-molecule drugs, including roughly a third of anticancer medicines [5]. They've also given us many of the major antibiotic classes still in clinical use. Paclitaxel from the Pacific yew, aspirin from willow-bark salicin, quinine from Cinchona bark: each one made the journey from folk remedy to clinical standard, and so did the antifungals, antiparasitics, and immunosuppressants that came after.

Nature was never the bottleneck. Our ability to search it systematically was. That's exactly the gap computational bioinformatics is now closing.

The Crisis Demanding a New Approach: AMR

Antimicrobial resistance isn't a future warning anymore, it's a present emergency. The ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) already account for a substantial share of the hardest-to-treat hospital infections worldwide [6].

WHO surveillance data put it plainly: roughly one in six laboratory-confirmed bacterial infections in 2023 involved drug-resistant organisms [7]. And that's not the ceiling, it's the current trajectory.

Conventional drug development can't fix this quickly. The path from discovery to an approved antibiotic usually takes ten to fifteen years and costs more than US\$2 billion [4]. Bacteria don't wait that long, they can pick up or spread resistance genes within years, sometimes months. The mismatch isn't a small inefficiency; it's structural. Closing it means working at a fundamentally different speed.

Natural products are especially compelling candidates here. Millions of years of co-evolution with microbial and fungal adversaries shaped their chemical diversity, and that shows up as a wide range of biological mechanisms. Some can hit multiple pathways at once, which makes it harder for a single resistance mutation to knock them out entirely. Combine that multiplicity of action with structural novelty rarely found in synthetic libraries, and phytochemicals and microbial metabolites become genuinely valuable starting points for antimicrobial drug discovery. Computational screening is what lets researchers sort through thousands of such compounds and prioritize the most promising ones, before a single experiment is even run.

The Digital Drug Hunter: How the Pipeline Works

Step 1: Building the Library

Every computational drug discovery project starts with a chemical library, and several open-access databases make building one fairly straightforward. COCONUT (Collection of Open Natural Products) is one of the largest open repositories for natural product research [8]. ZINC22 gives access to billions of commercially available compounds for virtual screening [9], while TCM Database@Taiwan catalogs more than 20,000 compounds drawn from traditional Chinese medicine [10]. Together, these resources let researchers put together focused candidate libraries for a given target fairly quickly.

Step 2: Molecular Docking

Molecular docking predicts how a small molecule fits into a target protein's active site, its pose, its affinity. Software like AutoDock Vina, Glide, and the GPU-accelerated Uni-Dock has made this kind of virtual screening faster and, importantly, more accessible for researchers working in resource-constrained settings [11]. It lets thousands of compounds get ranked computationally, something that would be far too slow and expensive to attempt at the bench.

Step 3: ADMET Prediction

A strong binding score alone isn't enough. A viable drug candidate also needs to be absorbed, distributed, metabolized, and excreted safely by the human body. That's where ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction comes in, it helps flag candidates with better pharmacokinetic and safety profiles before anyone commits to expensive lab testing. This matters more than it might seem: poor pharmacokinetics has historically been one of the biggest causes of late-stage drug failure [12]. Platforms like SwissADME, pkCSM, and

admetSAR 3.0 use machine learning to forecast these properties for every compound in the library [13].

Step 4: Molecular Dynamics Validation

Docking only gives a static snapshot of the protein–ligand interaction. Molecular dynamics (MD) simulation picks up where that leaves off, modeling how the complex behaves over time under conditions that mimic the physiological environment. Programs like GROMACS and AMBER handle the simulation itself, while post-simulation analyses such as MM-GBSA calculations sharpen the estimate of binding free energy, helping researchers figure out which candidates are actually stable enough to justify the cost of experimental testing.

Step 5: Experimental Validation

Docking predicts interactions. ADMET estimates drug-like properties. MD checks for stability. But none of that answers the real question, whether a candidate actually does anything biologically, and only lab experiments can settle that. For antimicrobial candidates, that usually means minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays, followed by mechanistic studies confirming the compound hits its predicted target. If results hold up, the next steps are animal models and, eventually, clinical validation. Computational tools narrow the search. Experimental biology answers it.




Figure 1: From nature to candidate drug, an integrated computational-experimental workflow

From Algorithm to Application

This framework isn't limited to one disease area. The same basic approach adapts to oncology, metabolic disease, and antimicrobial research alike, as these examples show.

In oncology, structure-based virtual screening flagged apigetrin, a flavonoid glycoside found in several medicinal plants, as a promising inhibitor of PI3K α , a protein frequently altered in head and neck squamous cell carcinoma [14]. It's a good example of computational methods doing double duty: explaining the molecular basis of a compound long used in traditional medicine, while also assessing its therapeutic potential.

In diabetes research, de novo in silico screening of more than 24,000 compounds against human pancreatic α -amylase turned up three candidates with stronger predicted binding than the reference drug acarbose [15]. Reaching that result through conventional wet-lab screening alone would likely have taken years.

In antimicrobial research, structural bioinformatics has flagged FDA-approved drugs that could potentially be repurposed against novel targets in multidrug-resistant *Acinetobacter baumannii* [16], a faster, cheaper route to new treatments than starting from scratch with novel compounds.

Case Study: A Computational Route Against MDR *Acinetobacter baumannii*

Acinetobacter baumannii has earned its reputation as one of the toughest hospital pathogens to treat, largely because it can pick up resistance to multiple antibiotic classes at once. A 2025 study took a structural bioinformatics approach, screening FDA-approved drugs against BaeR, a regulatory protein involved in antibiotic resistance signaling in *A. baumannii* [16].

The pipeline: FDA-approved drug library → BaeR protein target → molecular docking → top hits selected by binding score → ADMET filtering → MD simulation for stability → computational hits prioritized for experimental follow-up. Starting from already-approved drugs meant the study could skip years of safety profiling, a real shortcut for the repurposing strategy. The promising hits were identified computationally and put

forward as candidates for future experimental validation: a complete in silico drug repurposing workflow, start to finish.

Honest Limitations

Computational drug discovery is powerful, but it has real limits, and they're worth stating plainly. Four in particular stand out:

Docking scores $\neq$ biological activity. A good docking score doesn't guarantee a compound will actually work in a cell or organism. Every computational hit still needs experimental validation before anyone draws conclusions from it.

Flexible molecules are difficult to model. Docking algorithms often struggle with highly flexible compounds, which can produce false positives, and false positives eat up experimental resources that could go elsewhere.

Database gaps and bias. Natural product databases have grown fast, but they still capture only a fraction of Earth's chemical diversity. Marine natural products in particular remain underrepresented, and some regions and taxonomic groups are simply better cataloged than others.

Reproducibility. Screening protocols and selection criteria are reported inconsistently across studies, which makes comparing findings harder than it should be. The field needs more transparency in methods.

What Comes Next: AI, AlphaFold, and Genome Mining

Every step of this pipeline is now getting faster thanks to artificial intelligence. AlphaFold2 has predicted structures for over 214 million proteins with high accuracy [17], which has massively expanded the pool of druggable targets available for computational screening. Graph neural networks are getting better at predicting protein–ligand binding affinities, and generative AI models are starting to propose novel compound structures optimized for specific targets.

Metagenomics and genome mining are opening up another frontier entirely. Sequencing advances have uncovered huge reservoirs of biosynthetic gene clusters in soil and marine microorganisms, many capable of producing natural products no one has ever isolated or characterized. Computational tools can now predict the chemical structure of these molecules straight from their gene sequences, which means virtual screening can start before lab synthesis even begins.

It's worth being honest about what AI actually does here: it generates hypotheses, nothing more. No matter how sophisticated the model, prioritizing a compound computationally doesn't tell you whether it works in a living system. WHO's 2023 antibacterial pipeline analysis makes that distinction feel urgent, it found a critically thin clinical pipeline that predictions alone can't fill [18]. Experimental validation still has the final word.

Conclusion

For researchers in South Asia, Africa, and Latin America, regions rich in biodiversity but often short on funding, this convergence matters in a very practical way. It levels the playing field. Freely available computational tools, growing biological databases, and vast untapped natural resources are lowering the barriers to serious drug discovery research in ways that simply weren't possible a generation ago.

The logic underneath all of this is simple, even if the execution isn't. Nature supplies the chemical diversity, millions of years of evolutionary pressure that no synthetic chemistry program has managed to replicate. Bioinformatics lets us search that diversity systematically. AI helps narrow down the most promising leads. And experimental biology tells us, finally, what actually works. Not one of these pieces is enough on its own. Together, though, they're reshaping how the world searches for medicines it urgently needs.

References

- [1] Dias DA, Urban S, Roessner U. A Historical Overview of Natural Products in Drug Discovery. *Metabolites*. 2012;2(2):303–336.
- [2] Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. *Nat Rev Drug Discov*. 2021;20(3):200–216.
- [3] Naghavi M, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *Lancet*. 2024;404(10459):1199–1226.
- [4] DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. *J Health Econ*. 2016;47:20–33.
- [5] Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. *J Nat Prod*. 2020;83(3):770–803.
- [6] World Health Organization. WHO Bacterial Priority Pathogens List, 2024. Geneva: WHO; 2024.
- [7] World Health Organization. Global Antibiotic Resistance Surveillance Report 2025 (GLASS). Geneva: WHO; 2025.
- [8] Chandrasekhar V, et al. COCONUT 2.0: a comprehensive overhaul and curation of the collection of open natural products database. *Nucleic Acids Res*. 2025;53(D1):D634–D643.
- [9] Tingle BI, et al. ZINC-22 — A Free Multi-Billion-Scale Database of Tangible Compounds for Ligand Discovery. *J Chem Inf Model*. 2023;63(4):1166–1176.
- [10] Chen CY. TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico. *PLoS ONE*. 2011;6(1):e15939.
- [11] Yu Y, Cai C, Wang J, Bo Z, Zhu Z, Zheng H. Uni-Dock: GPU-accelerated docking enables ultralarge virtual screening. *J Chem Theory Comput*. 2023;19(11):3336–3345.
- [12] Kennedy T. Managing the drug discovery/development interface. *Drug Discov Today*. 1997;2(10):436–444.
- [13] Gu Y, et al. admetSAR 3.0: a comprehensive platform for ADMET properties. *Nucleic Acids Res*. 2024;52(W1):W432–W438.

-
- [14] Jia W, Cheng X. In Silico Discovery of a Novel Natural Product Targeting PI3K α for Head and Neck Squamous Cell Carcinoma. *Int J Mol Sci.* 2025;26(8):3565.
- [15] Ibrahim SO, Ayipo YO, et al. De novo in silico screening of natural products for antidiabetic drug discovery. *In Silico Pharmacol.* 2025;13(1):29.
- [16] Alagesan K, Nagarajan H, Jeyakanthan J. Repurposing FDA-approved drugs for combating tigecycline resistance in *Acinetobacter baumannii*: in silico screening against BaeR protein. *Mol Divers.* 2025;29(3):2243–2264.
- [17] Varadi M, et al. AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences. *Nucleic Acids Res.* 2024;52(D1):D368–D375.
- [18] Melchiorri D, Rocke T, Alm RA, Cameron AM, Gigante V. Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses. *Lancet Microbe.* 2025;6(3):100992.
- [19] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet.* 2022;399(10325):629–655.